KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

NCT05906524 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced HCC
Other Solid Tumors

Interventions

DRUG: KD6001
DRUG: Tislelizumab
DRUG: Bevacizumab

Sponsor

Shanghai Kanda Biotechnology Co., Ltd.